Chronic hepatitis C virus infection after treatment for pediatric malignancy
Chronic hepatitis C virus infection after treatment for pediatric malignancy
复制标题
DOI：
10.1182/blood.v90.3.1315.1315_1315_1320
复制
发表时间：
1997-08-01
期刊：
影响因子：
20.3
通讯作者：
Zanesco, L
中科院分区：
文献类型：
--
作者：
Cesaro, S;Petris, MG;Zanesco, L
通过第二代酶联免疫吸附试验和重组免疫印迹试验对 658 名已完成儿科恶性肿瘤治疗的患者的血清进行分析，以评估丙型肝炎病毒 (HCV) 血清阳性的患病率。所有 HCV 血清阳性患者均接受了详细的临床、实验室、病毒学和组织学研究，以分析 HCV 感染过程。 658 名患者中有 117 名 (17.8%) HCV 感染标志物呈阳性。在117名抗-HCV+患者中，41名（35%）乙型肝炎病毒感染标志物也呈阳性，伴或不伴有δ病毒感染标志物，91名（77.8%）既往接受过血液制品输注，25名（21.4%）在最近5年的随访中显示谷丙转氨酶（ALT）水平正常（其中11名从未出现过ALT水平异常）。其余 92 名患者的 ALT 水平高于正常范围上限。 117 名抗 HCV + 患者中有 81 名 (70%) 为 HCV-RNA(+)，大多数患者 (54%) 存在基因型 1b。在单变量分析中，慢性肝病的危险因素没有统计学意义。在这项研究中，接受儿童恶性肿瘤治疗的患者中丙型肝炎病毒感染的患病率较高。在约 20% 的抗 HCV+ 患者中，在 HCV 感染的流行病学中应考虑除输血以外的途径。经过 14 年的中位随访，抗 HCV+ 阳性患者的慢性肝病并未进展为肝衰竭，(C) 1997，美国血液学会。
Sera of 658 patients who had completed treatment for pediatric malignancy were analyzed by a second-generation enzyme-linked immunosorbent assay and recombinant immunoblot assay test to assess the prevalence of hepatitis C virus (HCV)-seropositivity. All HCV-seropositive patients underwent detailed clinical, laboratory, virologic, and histologic study to analyze the course of HCV infection. One hundred seventeen of the 658 patients (17.8%) were positive for HCV infection markers. Among the 117 anti-HCV+ patients, 41 (35%) were also positive for markers of hepatitis B virus infection with or without delta virus infection markers, 91 (77.8%) had previously received blood product transfusions, and 25 (21.4%) showed a normal alanine aminotransferase (ALT) level during the last 5-year follow-up (11 of them never had abnormal ALT levels). The remaining 92 patients showed ALT levels higher than the upper limit of normal range. Eighty-one of 117 (70%) anti-HCV+ patients were HCV-RNA(+), with genotype 1b being present in most patients (54%). In univariate analysis, no risk factor for chronic liver disease was statistically significant. In this study, the prevalence of HCV infection was high in patients who were treated for a childhood malignancy. In about 20% of anti-HCV+ patients, routes other than blood transfusions are to be considered in the epidemiology of HCV infection, After a 14-year median follow-up, chronic liver disease of anti-HCV+ positive patients did not show progression to liver failure, (C) 1997 by The American Society of Hematology.